SCHEDULE: Armistice Capital Discloses 7.57% Stake in Voyager Therapeutics
Beneficial Ownership Disclosure
Armistice Capital, LLC and Steven Boyd reported a 7.57% beneficial ownership stake in Voyager Therapeutics, Inc. as of September 30, 2025.
Summary
- Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 4,200,000 shares of Voyager Therapeutics, Inc. common stock.
- This ownership represents 7.57% of the company's outstanding common stock.
- The percentage is calculated based on 55,468,806 shares outstanding as of August 1, 2025, as reported in the Issuer's Form 10-Q filed on August 6, 2025.
- The reporting persons, Armistice Capital, LLC and Steven Boyd, have shared voting and shared dispositive power over all 4,200,000 beneficially owned shares.
- This filing is an Amendment No. 6 to a Schedule 13G, indicating a passive investment without the purpose or effect of changing or influencing the control of the issuer.
Sentiment
Score: 7
Explanation: The filing indicates a significant and continued passive investment by an institutional fund, which can be viewed positively as a vote of confidence. However, it's a routine disclosure and doesn't provide new operational or financial insights into the company itself.
Positives
- A significant institutional investor, Armistice Capital, maintains a substantial stake in Voyager Therapeutics, potentially signaling continued confidence in the company's long-term prospects.
Future Outlook
NA
Industry Context
This filing indicates continued institutional interest in the biotechnology sector, specifically in companies like Voyager Therapeutics, which are often subject to significant investor scrutiny due to their development-stage nature and potential for high growth or risk. The disclosure of a substantial passive stake by an investment manager like Armistice Capital is a routine transparency measure for significant holdings.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2025-08-01 | Date as of which 55,468,806 shares outstanding were reported on Issuer's Form 10-Q. |
| 2025-09-30 | Date of event which required the filing of this statement, reflecting the beneficial ownership. |
| 2025-11-14 | Date the Schedule 13G Amendment No. 6 was signed and filed. |
Recommendation
holdThe Schedule 13G filing primarily discloses a significant passive ownership stake by Armistice Capital and Steven Boyd in Voyager Therapeutics. While the continued presence of a substantial institutional investor can be seen as a positive signal of confidence, this filing alone does not provide new operational or financial data to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current positions while awaiting further fundamental updates from the company.
Keywords
Voyager Therapeutics, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Biotechnology, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.